Comparative Pharmacology
Head-to-head clinical analysis: NUTROPIN versus SEROSTIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUTROPIN versus SEROSTIM.
NUTROPIN vs SEROSTIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased IGF-1 production and subsequent anabolic, lipolytic, and anti-insulin effects.
SEROSTIM is a recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased production of insulin-like growth factor 1 (IGF-1). It promotes linear growth, protein synthesis, and lipolysis.
0.006 mg/kg subcutaneously once daily (maximum 0.025 mg/kg/day). May also be administered intramuscularly at 0.1-0.3 mg/kg per week divided into 3-7 doses.
0.1 mg/kg subcutaneously once daily for 4 weeks; alternatively, 4 mg subcutaneously once daily for 4 weeks for patients ≥35 kg.
None Documented
None Documented
Terminal elimination half-life of 3.9–4.1 hours following subcutaneous administration; intravenous half-life approximately 20–30 minutes due to rapid distribution.
Terminal half-life of approximately 2-3 hours after subcutaneous administration; prolonged in renal impairment (up to 6-8 hours).
Primarily renal; >99% of absorbed dose eliminated via glomerular filtration and tubular reabsorption, with minimal biliary excretion (<1%).
Primarily renal (90% metabolized in liver and kidneys; 0.1% excreted unchanged in urine); biliary/fecal negligible.
Category C
Category C
Growth Hormone
Growth Hormone